Drug Trial Radar · NCT06508320
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)
Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
931
Actual
Start
Jul 15, 2024
Primary completion
Sep 25, 2025
Study completion Sep 25, 2025
Sponsor
- Lead sponsor
- ModernaTX, Inc.Moderna (MRNA)
- Sponsor type
- Industry
- First posted
- Jul 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity in relation to the product attributes of mRNA-1083 vaccine when administered as a single intramuscular (IM) injection in adults ≥50 to \<65 years of age.
Conditions
- Influenza
- SARS-CoV-2
Interventions
mRNA-1083Biological
IM injection in a deltoid muscle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibody for Seasonal Influenza A and B StrainsTime frame: Day 29
- Geometric Mean Titer (GMT) of Neutralizing Antibody for SARS-CoV-2Time frame: Day 29
- Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)Time frame: From the day of study injection through 6 subsequent days (Up to 7 days)
- Number of Participants With Unsolicited Adverse Events (AEs)Time frame: From the day of study injection through 27 subsequent days (Up to 28 days)
- Number of Participants With Medically Attended AEs (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Study DiscontinuationTime frame: From Day 1 to End of Study (Up to 6 Months)
Locations
17 sites in 2 countries. Site status is shown where the registry gives one.
Indago Research & Health Center, Inc.
Hialeah, Florida
Cenexel RCA
Hollywood, Florida
Suncoast Research Group, LLC DBA Flourish Research
Miami, Florida
Cenexel IRA
Decatur, Georgia
DM Clinical Research - River Forest
River Forest, Illinois
JCCT
Lenexa, Kansas
Hassman Research Institute - Berlin - CenExel - PPDS
Marlton, New Jersey
DM Clinical Research - Philadelphia
Philadelphia, Pennsylvania
DM Clinical Research - Cyfair Clinical Research Center - PPDS
Houston, Texas
Clinical Trials of Texas, LLC DBA Flourish Research
San Antonio, Texas
DM Clinical Research - Sugarland
Sugar Land, Texas
DM Clinical Research - Tomball MDC
Tomball, Texas
Diex Recherche Québec Inc.
Québec, Canada
Centricity Research
Toronto, Ontario, Canada
Centricity Research
Toronto, Ontario, Canada
Centricity Research
Pointe-Claire, Quebec, Canada
Diex Recherche Sherbrooke Inc.
Sherbrooke, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.